NanoVibronix ( (NAOV) ) has issued an update.
On March 14, 2025, NanoVibronix, Inc. announced that an independent study of its UroShield® device was published in The Australian and New Zealand Continence Journal. The study demonstrated UroShield’s effectiveness in reducing catheter-associated urinary tract infections (CAUTIs) and blockages, significantly improving patient comfort and reducing healthcare costs. The findings suggest that UroShield could ease nursing workloads and lead to measurable cost savings for healthcare providers.
More about NanoVibronix
NanoVibronix, Inc. is a medical device company headquartered in Tyler, Texas, with research and development in Nesher, Israel. The company specializes in developing medical devices using patented low intensity surface acoustic wave (SAW) technology. Its primary products, PainShield® and UroShield®, are portable devices designed for home or care setting use, focusing on applications like biofilm disruption, bacterial colonization prevention, and pain relief.
YTD Price Performance: -59.49%
Average Trading Volume: 3,661,801
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $2.14M
See more insights into NAOV stock on TipRanks’ Stock Analysis page.